PURPOSE: The objective of this study was to evaluate the long-term safety and pharmacokinetic profile of a dexamethasone-loaded poly-epsilon-caprolactone (PCL) intravitreous implant. METHODS: The PCL devices were prepared by compression and were inserted into the vitreous of pigmented rabbits. At different time points, vitreous samples were retrieved, and dexamethasone concentration was analyzed by high-performance liquid chromatography. The biodegradation of the implants was evaluated by scanning electron microscopy, and the dexamethasone remaining was evaluated at the end of follow-up. Clinical and histologic examinations were performed to evaluate the implant's tolerance. RESULTS: The PCL implant allows for a controlled and prolonged delivery of dexamethasone in rabbits eyes since it released the drug within the therapeutic range for at least 55 weeks. At 55 weeks approximately 79% of the drug was still present in the implant. Biodegradation study showed that PCL implants degradation is very slow. Clinical and histologic observations showed that the devices were very well tolerated in the rabbit eye. CONCLUSIONS: This study demonstrates the feasibility and tolerance of intravitreous PCL drug delivery systems, which can offer a wide range of applications for intraocular drug delivery because of their controlled and prolonged release over months or even years.
PURPOSE: The objective of this study was to evaluate the long-term safety and pharmacokinetic profile of a dexamethasone-loaded poly-epsilon-caprolactone (PCL) intravitreous implant. METHODS: The PCL devices were prepared by compression and were inserted into the vitreous of pigmented rabbits. At different time points, vitreous samples were retrieved, and dexamethasone concentration was analyzed by high-performance liquid chromatography. The biodegradation of the implants was evaluated by scanning electron microscopy, and the dexamethasone remaining was evaluated at the end of follow-up. Clinical and histologic examinations were performed to evaluate the implant's tolerance. RESULTS: The PCL implant allows for a controlled and prolonged delivery of dexamethasone in rabbits eyes since it released the drug within the therapeutic range for at least 55 weeks. At 55 weeks approximately 79% of the drug was still present in the implant. Biodegradation study showed that PCL implants degradation is very slow. Clinical and histologic observations showed that the devices were very well tolerated in the rabbit eye. CONCLUSIONS: This study demonstrates the feasibility and tolerance of intravitreous PCL drug delivery systems, which can offer a wide range of applications for intraocular drug delivery because of their controlled and prolonged release over months or even years.
Authors: William R Lykins; Ellen Luecke; Daniel Johengen; Ariane van der Straten; Tejal A Desai Journal: Drug Deliv Transl Res Date: 2017-12 Impact factor: 4.617
Authors: J H Ashton; J A M Mertz; J L Harper; M J Slepian; J L Mills; D V McGrath; J P Vande Geest Journal: Acta Biomater Date: 2010-09-09 Impact factor: 8.947
Authors: Kevin D Lance; Daniel A Bernards; Natalie A Ciaccio; Samuel D Good; Thaís S Mendes; Max Kudisch; Elliot Chan; Mynna Ishikiriyama; Robert B Bhisitkul; Tejal A Desai Journal: Drug Deliv Transl Res Date: 2016-12 Impact factor: 4.617
Authors: Daniel A Bernards; Robert B Bhisitkul; Paula Wynn; Mark R Steedman; On-Tat Lee; Fergus Wong; Somanus Thoongsuwan; Tejal A Desai Journal: J Ocul Pharmacol Ther Date: 2013-02-07 Impact factor: 2.671
Authors: Kevin D Lance; Samuel D Good; Thaís S Mendes; Mynna Ishikiriyama; Patrick Chew; Laurel S Estes; Kazuhito Yamada; Sri Mudumba; Robert B Bhisitkul; Tejal A Desai Journal: Invest Ophthalmol Vis Sci Date: 2015-11 Impact factor: 4.799
Authors: A T Christiansen; S L Tao; M Smith; G E Wnek; J U Prause; M J Young; H Klassen; H J Kaplan; M la Cour; J F Kiilgaard Journal: Stem Cells Int Date: 2012-03-15 Impact factor: 5.443
Authors: Paulina García-Estrada; Miguel A García-Bon; Edgar J López-Naranjo; Dulce N Basaldúa-Pérez; Arturo Santos; Jose Navarro-Partida Journal: Pharmaceutics Date: 2021-05-12 Impact factor: 6.321